---
figid: PMC4539069__ECAM2015-975632.001
figtitle: Proposed model for the complex cross talk between various receptors and
  mediators in early phase response in allergic rhinitis
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Arabidopsis thaliana
- Homo sapiens
pmcid: PMC4539069
filename: ECAM2015-975632.001.jpg
figlink: /pmc/articles/PMC4539069/figure/fig1/
number: F1
caption: 'Proposed model for the complex cross talk between various receptors and
  mediators in early phase response in allergic rhinitis. 1: nerve growth factor (NGF)
  activates tyrosine kinase A (TrkA) receptor which in turn increases production and
  release of substance P (SP). Activation of TrkA receptor also initiates signalling
  via the PI3K/PIP3 pathway to increase expression and sensitivity of transient receptor
  potential vallinoid (TRPV1) receptor. 2: chemokine receptors (CCR2, CCR3, and CXCR8)
  sensitize TRPV1 receptor via a PLCβ/PKC pathway. 3: TRPV1 receptor increases production
  and release of proinflammatory neuropeptides SP and CGRP which act synergistically
  to promote degranulation of primed mast cells. Histamine released by mast cells
  activates histamine 1 receptor (H1R) producing signalling via the phospholipase
  A2/lipoxygenase pathway to activate TRPV1, triggering early phase allergic inflammatory
  response. 4: chemokine receptors are heterologously desensitized by both adenosine
  (A2a) receptors and opioid receptors (MOR, DOR, and KOR). 5: Substance P is inhibited
  by met-enkephalin via Mu opioid receptors (MOR). A2a: adenosine 2a receptor, CCR2,
  CCR3: CC chemokine receptors 2 & 3, CXCR8: CXC chemokine receptor 8, PLCβ: phospholipase
  C β, PKC: protein kinase C, NGF: nerve growth factor, TRPV1: transient receptor
  potential vallinoid 1, TrkA: tyrosine kinase A receptor, H1R: histamine 1 receptor,
  SP: substance P, CGRP: calcitonin gene-related peptide, PI3K/PIP3: phosphatidylinositol
  3 kinase/phosphatidylinositol phosphate 3 pathway, PLA2/LO: phospholipase A2/lipoxygenase
  pathway, MOR: Mu opioid receptor, DOR: delta opioid receptor, KOR: kappa opioid
  receptor, and MEK: met-enkephalin.'
papertitle: Mediators, Receptors, and Signalling Pathways in the Anti-Inflammatory
  and Antihyperalgesic Effects of Acupuncture.
reftext: John L. McDonald, et al. Evid Based Complement Alternat Med. 2015;2015:975632.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9388725
figid_alias: PMC4539069__F1
figtype: Figure
redirect_from: /figures/PMC4539069__F1
ndex: b5f7dc3c-dee8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4539069__ECAM2015-975632.001.html
  '@type': Dataset
  description: 'Proposed model for the complex cross talk between various receptors
    and mediators in early phase response in allergic rhinitis. 1: nerve growth factor
    (NGF) activates tyrosine kinase A (TrkA) receptor which in turn increases production
    and release of substance P (SP). Activation of TrkA receptor also initiates signalling
    via the PI3K/PIP3 pathway to increase expression and sensitivity of transient
    receptor potential vallinoid (TRPV1) receptor. 2: chemokine receptors (CCR2, CCR3,
    and CXCR8) sensitize TRPV1 receptor via a PLCβ/PKC pathway. 3: TRPV1 receptor
    increases production and release of proinflammatory neuropeptides SP and CGRP
    which act synergistically to promote degranulation of primed mast cells. Histamine
    released by mast cells activates histamine 1 receptor (H1R) producing signalling
    via the phospholipase A2/lipoxygenase pathway to activate TRPV1, triggering early
    phase allergic inflammatory response. 4: chemokine receptors are heterologously
    desensitized by both adenosine (A2a) receptors and opioid receptors (MOR, DOR,
    and KOR). 5: Substance P is inhibited by met-enkephalin via Mu opioid receptors
    (MOR). A2a: adenosine 2a receptor, CCR2, CCR3: CC chemokine receptors 2 & 3, CXCR8:
    CXC chemokine receptor 8, PLCβ: phospholipase C β, PKC: protein kinase C, NGF:
    nerve growth factor, TRPV1: transient receptor potential vallinoid 1, TrkA: tyrosine
    kinase A receptor, H1R: histamine 1 receptor, SP: substance P, CGRP: calcitonin
    gene-related peptide, PI3K/PIP3: phosphatidylinositol 3 kinase/phosphatidylinositol
    phosphate 3 pathway, PLA2/LO: phospholipase A2/lipoxygenase pathway, MOR: Mu opioid
    receptor, DOR: delta opioid receptor, KOR: kappa opioid receptor, and MEK: met-enkephalin.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - mor
  - dor
  - DOR
  - dl
  - Dsor1
  - Mtk
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - norpA
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - lds
  - act
  - Act5C
  - .na.character
  - Act42A
  - Actbeta
  - Pla
  - chb
  - CCR2
  - GRP7
  - CRTISO
  - CCR3
  - GH9A1
  - VPS34
  - PIP3
  - NGF
  - IGKV2D-29
  - NTRK1
  - OPRM1
  - OPRD1
  - TP53INP2
  - OPRK1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - TRPV1
  - CALCA
  - S100A12
  - SERPINA3
  - ACTG1
  - ACTG2
  - FHL5
  - ACOT7
  - ACTBL2
  - POTEKP
  - POTEM
  - SPACA9
  - SPG21
  - HRH1
  - Adenosine
  - Histamine
  - Cancer
---
